Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Cardiovascular Research of Knoxville

Neither a doctor nor a teaching hospital

Research payments

$1,369,080

429 payments

Through program year 2025, Cardiovascular Research of Knoxville is reported as receiving $1,369,080 in research payments, across 429 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $10,228 3
2024 Research $156,985 18
2023 Research $78,404 33
2022 Research $295,537 127
2021 Research $415,633 144
2020 Research $215,884 59
2019 Research $196,409 45

Breakdown

Who paid Research payments · program years 2019–2025
  1. CSL Behring $855,114 156 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $239,290 55 payments
  3. Esperion Therapeutics, Inc. $100,186 169 payments
  4. Akcea Therapeutics, Inc. $45,173 7 payments
  5. Merck Sharp & Dohme Corporation $35,107 11 payments
  6. AstraZeneca Pharmaceuticals LP $30,695 4 payments
  7. Amgen Inc. $29,018 12 payments
  8. Novartis Pharmaceuticals Corporation $23,830 3 payments
  9. E.R. Squibb & Sons, L.L.C. $4,507 1 payment
  10. Amarin Pharma Inc. $3,268 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome $743,558 132 payments
  2. Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II $111,556 24 payments
  3. BAY94-8862 LCM HFmr/pEF (EF 40%) $100,354 24 payments
  4. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $100,186 169 payments
  5. A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) $56,211 9 payments
  6. BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti $44,555 10 payments
  7. Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction $38,170 12 payments
  8. HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease. $27,300 4 payments
  9. Dapagliflozin in Acute Decompensated Heart Failure $22,825 3 payments
  10. Isis 678354-Cs2 $20,129 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record